Dihydrotestosterone biosynthesis

The term "Dihydrotestosterone biosynthesis" refers to a series of biochemical reactions responsible for producing dihydrotestosterone (DHT), a potent androgen hormone, from steroid precursors. There are multiple distinct biosynthetic pathways: - The canonical (classical) pathway converts testosterone—synthesized from androstenedione or androstenediol—into DHT via the enzyme 5α-reductase, mainly type 2 (SRD5A2)[3][4]. - The "backdoor" pathway produces DHT directly from progesterone or 17α-hydroxyprogesterone intermediates through sequential actions of 5α-reductases (SRD5A1/2/3), 3α-hydroxysteroid dehydrogenases (AKR1C1/2/3/4), 17β-hydroxysteroid dehydrogenases (HSD17B3/6), CYP enzymes (CYP17A1), and others, bypassing testosterone as an intermediate[3][1]. - DHT plays a critical role in sexual differentiation, prostate function, hair patterning, and various pathologies including prostate cancer and androgenic disorders[3][4][5]. - Therapeutic drugs (e.g., finasteride, dutasteride, abiraterone) target key enzymes in these pathways, primarily 5α-reductase and CYP17A1, to limit DHT production in conditions such as benign prostatic hyperplasia, prostate cancer, and androgenic alopecia, but may cause side effects related to suppressed androgen activity[4][6][10]. Because "Dihydrotestosterone biosynthesis" describes a pathway and not a single protein, molecule, or direct drug target, its use as a therapeutic target per se is incorrect; individual enzymes within this pathway are the actual molecular targets.

Other names

DHT biosynthesisDihydrotestosterone synthesisAndrogen backdoor pathwayBackdoor DHT biosynthesisClassic androgen biosynthesis

Inhibition of 5α-reductase blocks conversion of testosterone to DHT; Inhibition of CYP17A1 impairs androgen (including DHT) synthesis upstream[4][6][10]